<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pretrained Joint Predictions for Scalable Batch Bayesian Optimization of Molecular Designs - Health AI Hub</title>
    <meta name="description" content="This paper introduces a novel approach for scalable Batch Bayesian Optimization (BO) of molecular designs, a critical bottleneck in drug development. It achieve">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Pretrained Joint Predictions for Scalable Batch Bayesian Optimization of Molecular Designs</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.10590v1" target="_blank">2511.10590v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-13
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Miles Wang-Henderson, Ben Kaufman, Edward Williams, Ryan Pederson, Matteo Rossi, Owen Howell, Carl Underkoffler, Narbe Mardirossian, John Parkhill
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.10590v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.10590v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a novel approach for scalable Batch Bayesian Optimization (BO) of molecular designs, a critical bottleneck in drug development. It achieves this by leveraging Epistemic Neural Networks (ENNs) to construct scalable probabilistic surrogates for binding affinity, integrating representations from large structure-informed models. A key innovation involves pretraining ENN prior networks on synthetic data, leading to significantly faster discovery of potent molecular inhibitors, demonstrating up to a 10x acceleration.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is highly relevant to medicine as it directly tackles the inefficiency in early-stage drug discovery, a major bottleneck in bringing new treatments to patients. By accelerating the identification of promising molecular designs, it can significantly reduce the time and cost associated with developing drugs for various diseases.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI methodology (Bayesian Optimization with Epistemic Neural Networks) is applied to accelerate the identification and optimization of molecular designs for drug development, specifically for discovering new drug candidates like EGFR inhibitors.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the critical bottleneck of batched synthesis and testing in molecular design within drug development by proposing advanced computational surrogates.</li>
                    
                    <li>Introduces scalable probabilistic surrogates of binding affinity specifically designed for use in Batch Bayesian Optimization (Batch BO), crucial for parallel acquisition functions.</li>
                    
                    <li>Utilizes Epistemic Neural Networks (ENNs) to obtain scalable joint predictive distributions of binding affinity, building upon representations from large structure-informed biomolecular foundation models.</li>
                    
                    <li>Highlights the importance of prior networks within ENNs and demonstrates a novel strategy to pretrain them on synthetic data to enhance downstream Batch BO performance.</li>
                    
                    <li>Achieved a significant acceleration in rediscovering known potent EGFR inhibitors on a semi-synthetic benchmark, requiring up to 5x fewer iterations.</li>
                    
                    <li>Demonstrated superior performance in identifying potent inhibitors from a real-world small-molecule library, completing the task in up to 10x fewer iterations.</li>
                    
                    <li>Offers a promising and highly efficient solution for accelerating large-scale drug discovery applications by substantially reducing experimental design-test cycles.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The methodology centers on Batch Bayesian Optimization (BO) for molecular design. It employs Epistemic Neural Networks (ENNs) to create scalable probabilistic surrogates for binding affinity, leveraging molecular representations from large structure-informed models. A core aspect is the pretraining of ENN prior networks on synthetic data, enabling rapid sampling from joint predictive densities necessary for efficient parallel acquisition functions in Batch BO.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The study's key findings demonstrate a substantial increase in the efficiency of molecular design. The proposed method rediscovered potent EGFR inhibitors on a semi-synthetic benchmark in up to 5 times fewer iterations. Furthermore, it identified potent inhibitors from a real-world small-molecule library in up to 10 times fewer iterations, showcasing a significant acceleration in the drug discovery process.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The enhanced efficiency in identifying potent molecular inhibitors has a direct and profound clinical impact by accelerating the preclinical phase of drug discovery. This can lead to a faster pipeline for identifying drug candidates, potentially shortening the overall drug development timeline and reducing the cost of bringing new, effective therapeutics to patients, particularly for challenging diseases like cancer where EGFR inhibitors are relevant.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Limitations are not explicitly mentioned in the abstract.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Future research directions are not explicitly mentioned in the abstract.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Drug Development</span>
                    
                    <span class="tag">Oncology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Bayesian Optimization</span>
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Molecular Design</span>
                    
                    <span class="tag tag-keyword">Epistemic Neural Networks</span>
                    
                    <span class="tag tag-keyword">Binding Affinity</span>
                    
                    <span class="tag tag-keyword">Foundation Models</span>
                    
                    <span class="tag tag-keyword">Pretraining</span>
                    
                    <span class="tag tag-keyword">EGFR Inhibitors</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Batched synthesis and testing of molecular designs is the key bottleneck of drug development. There has been great interest in leveraging biomolecular foundation models as surrogates to accelerate this process. In this work, we show how to obtain scalable probabilistic surrogates of binding affinity for use in Batch Bayesian Optimization (Batch BO). This demands parallel acquisition functions that hedge between designs and the ability to rapidly sample from a joint predictive density to approximate them. Through the framework of Epistemic Neural Networks (ENNs), we obtain scalable joint predictive distributions of binding affinity on top of representations taken from large structure-informed models. Key to this work is an investigation into the importance of prior networks in ENNs and how to pretrain them on synthetic data to improve downstream performance in Batch BO. Their utility is demonstrated by rediscovering known potent EGFR inhibitors on a semi-synthetic benchmark in up to 5x fewer iterations, as well as potent inhibitors from a real-world small-molecule library in up to 10x fewer iterations, offering a promising solution for large-scale drug discovery applications.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>